Procept Biorobotics Net Worth
Procept Biorobotics Net Worth Breakdown | PRCT |
Procept Biorobotics Net Worth Analysis
Procept Biorobotics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Procept Biorobotics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Procept Biorobotics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Procept Biorobotics' net worth analysis. One common approach is to calculate Procept Biorobotics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Procept Biorobotics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Procept Biorobotics' net worth. This approach calculates the present value of Procept Biorobotics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Procept Biorobotics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Procept Biorobotics' net worth. This involves comparing Procept Biorobotics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Procept Biorobotics' net worth relative to its peers.
Enterprise Value |
|
To determine if Procept Biorobotics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Procept Biorobotics' net worth research are outlined below:
The company reported the previous year's revenue of 224.5 M. Net Loss for the year was (91.41 M) with profit before overhead, payroll, taxes, and interest of 156.23 M. | |
Procept Biorobotics Corp currently holds about 269.81 M in cash with (99.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.05. | |
Over 93.0% of the company shares are owned by institutional investors | |
Latest headline from gurufocus.com: PROCEPT BioRobotics Corp Achieves Milestone with New Category I CPT Code for Aquablation ... |
Procept Biorobotics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Procept Biorobotics Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Procept Biorobotics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
27th of February 2024 Upcoming Quarterly Report | View | |
25th of April 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
27th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Procept Biorobotics Target Price Consensus
Procept target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Procept Biorobotics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
10 | Strong Buy |
Most Procept analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Procept stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Procept Biorobotics Corp, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationProcept Biorobotics Target Price Projection
Procept Biorobotics' current and average target prices are 57.05 and 76.88, respectively. The current price of Procept Biorobotics is the price at which Procept Biorobotics Corp is currently trading. On the other hand, Procept Biorobotics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Procept Biorobotics Market Quote on 21st of July 2025
Target Price
Analyst Consensus On Procept Biorobotics Target Price
Know Procept Biorobotics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Procept Biorobotics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Procept Biorobotics Corp backward and forwards among themselves. Procept Biorobotics' institutional investor refers to the entity that pools money to purchase Procept Biorobotics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Bank Of America Corp | 2025-03-31 | 809.5 K | Axa Sa | 2025-03-31 | 787 K | Westfield Capital Management Company, L.p. | 2025-03-31 | 748.6 K | Jpmorgan Chase & Co | 2025-03-31 | 716.3 K | Champlain Investment Partners, Llc | 2025-03-31 | 676.2 K | Mirae Asset Global Etfs Holdings Ltd. | 2025-03-31 | 661.8 K | Lord, Abbett & Co Llc | 2025-03-31 | 544.7 K | Millennium Management Llc | 2025-03-31 | 543 K | Federated Hermes Inc | 2025-03-31 | 539.2 K | Fmr Inc | 2025-03-31 | 8.2 M | Vanguard Group Inc | 2025-03-31 | 5.1 M |
Follow Procept Biorobotics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.23 B.Market Cap |
|
Project Procept Biorobotics' profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.17) | (0.18) | |
Return On Capital Employed | (0.20) | (0.21) | |
Return On Assets | (0.17) | (0.18) | |
Return On Equity | (0.23) | (0.24) |
When accessing Procept Biorobotics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Procept Biorobotics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Procept Biorobotics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Procept Biorobotics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Procept Biorobotics Corp. Check Procept Biorobotics' Beneish M Score to see the likelihood of Procept Biorobotics' management manipulating its earnings.
Evaluate Procept Biorobotics' management efficiency
Procept Biorobotics Corp has return on total asset (ROA) of (0.1336) % which means that it has lost $0.1336 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2762) %, meaning that it created substantial loss on money invested by shareholders. Procept Biorobotics' management efficiency ratios could be used to measure how well Procept Biorobotics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.18 in 2025. Return On Capital Employed is likely to drop to -0.21 in 2025. At this time, Procept Biorobotics' Non Current Liabilities Total is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 381.7 K in 2025, whereas Total Current Liabilities is likely to drop slightly above 31.5 M in 2025.Last Reported | Projected for Next Year | ||
Book Value Per Share | 7.72 | 8.10 | |
Tangible Book Value Per Share | 7.70 | 8.08 | |
Enterprise Value Over EBITDA | (48.10) | (50.50) | |
Price Book Value Ratio | 10.43 | 10.96 | |
Enterprise Value Multiple | (48.10) | (50.50) | |
Price Fair Value | 10.43 | 10.96 | |
Enterprise Value | 1.6 B | 1.4 B |
Procept Biorobotics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue 12.0184 | Revenue | Quarterly Revenue Growth 0.553 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Procept Biorobotics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Procept Biorobotics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Procept Biorobotics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Procept Biorobotics Corporate Filings
F4 | 12th of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 11th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
30th of May 2025 Other Reports | ViewVerify | |
10Q | 2nd of May 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Procept Biorobotics Earnings Estimation Breakdown
The calculation of Procept Biorobotics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Procept Biorobotics is estimated to be -0.4125 with the future projection ranging from a low of -0.49 to a high of -0.31. Please be aware that this consensus of annual earnings estimates for Procept Biorobotics Corp is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.49 Lowest | Expected EPS | -0.31 Highest |
Procept Biorobotics Earnings Projection Consensus
Suppose the current estimates of Procept Biorobotics' value are higher than the current market price of the Procept Biorobotics stock. In this case, investors may conclude that Procept Biorobotics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Procept Biorobotics' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2025 | Current EPS (TTM) | |
10 | 88.66% | -0.45 | -0.4125 | -1.69 |
Procept Biorobotics Earnings per Share Projection vs Actual
Actual Earning per Share of Procept Biorobotics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Procept Biorobotics Corp predict the company's earnings will be in the future. The higher the earnings per share of Procept Biorobotics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Procept Biorobotics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Procept Biorobotics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Procept Biorobotics should always be considered in relation to other companies to make a more educated investment decision.Procept Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Procept Biorobotics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-04-29 | 2025-03-31 | -0.4913 | -0.45 | 0.0413 | 8 | ||
2025-02-25 | 2024-12-31 | -0.34 | -0.35 | -0.01 | 2 | ||
2024-10-30 | 2024-09-30 | -0.49 | -0.4 | 0.09 | 18 | ||
2024-08-01 | 2024-06-30 | -0.52 | -0.5 | 0.02 | 3 | ||
2024-05-01 | 2024-03-31 | -0.56 | -0.51 | 0.05 | 8 | ||
2024-02-27 | 2023-12-31 | -0.44 | -0.54 | -0.1 | 22 | ||
2023-11-08 | 2023-09-30 | -0.51 | -0.51 | 0.0 | 0 | ||
2023-07-27 | 2023-06-30 | -0.57 | -0.56 | 0.01 | 1 | ||
2023-04-27 | 2023-03-31 | -0.58 | -0.63 | -0.05 | 8 | ||
2023-02-28 | 2022-12-31 | -0.54 | -0.56 | -0.02 | 3 | ||
2022-11-03 | 2022-09-30 | -0.48 | -0.51 | -0.03 | 6 | ||
2022-08-04 | 2022-06-30 | -0.48 | -0.43 | 0.05 | 10 | ||
2022-05-05 | 2022-03-31 | -0.47 | -0.39 | 0.08 | 17 | ||
2022-03-08 | 2021-12-31 | -0.39 | -0.42 | -0.03 | 7 | ||
2021-11-04 | 2021-09-30 | -0.42 | -1.22 | -0.8 | 190 | ||
2021-09-16 | 2021-06-30 | -0.4 | -0.41 | -0.01 | 2 | ||
2021-06-30 | 2021-03-31 | 0 | -2.6268 | -2.6268 | 0 | ||
2021-03-31 | 2020-12-31 | 0 | -2.6268 | -2.6268 | 0 | ||
2020-12-31 | 2020-09-30 | 0 | -3.028 | -3.028 | 0 | ||
2020-09-30 | 2020-06-30 | 0 | -3.028 | -3.028 | 0 | ||
2020-06-30 | 2020-03-31 | 0 | -4.5621 | -4.5621 | 0 | ||
2020-03-31 | 2019-12-31 | 0 | -4.5621 | -4.5621 | 0 |
Procept Biorobotics Corporate Management
Matthew CFA | Vice Relations | Profile | |
Christofer Christoforou | Senior Operations | Profile | |
Hisham Shiblaq | Executive Officer | Profile | |
Stacey Porter | Chief Officer | Profile | |
Minni Vittal | VP Officer | Profile |
Additional Tools for Procept Stock Analysis
When running Procept Biorobotics' price analysis, check to measure Procept Biorobotics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Procept Biorobotics is operating at the current time. Most of Procept Biorobotics' value examination focuses on studying past and present price action to predict the probability of Procept Biorobotics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Procept Biorobotics' price. Additionally, you may evaluate how the addition of Procept Biorobotics to your portfolios can decrease your overall portfolio volatility.